凯睿思生命科学
CAI
30.56
-1.20
-3.78%
凯睿思生命科学
US · CAI
#1669 按市值排名
上市于 2025
30.56
-1.20
-3.78%
实时 - 追踪5344个代码 - 心跳于11秒前
· 2026-10-16 20:01
最新新闻
-
公司公告
UOB Kay Hian: Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)-NOTIFICATION FOR SUBSTANTIAL SHAREHOLDER - U.I.P. HOLDINGS LIMITEDSGX · 2026/9/8
-
公司公告
UOB Kay Hian: Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)-NOTIFICATION FOR SUBSTANTIAL SHAREHOLDER - U.I.P. HOLDINGS LIMITEDSGX · 2026/9/3
-
评级变动
I-MAB Buy Rating: Strategic Pivot to U.S. Market and Promising PipelineTipRanks · 2024/2/12
-
Trump: The U.S.-Iran war has reached a critical juncture, and I am facing a major decision.cls.cn · 2026/9/18
-
Fed's Barr Says Resilience Of U.S. Economy Is Striking; I Don't Have Recession In My Base Case; Momentum Seems To Be Building In The EconomyBenzinga · 2026/9/30
-
公司公告
UOB Kay Hian: Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)-NOTIFICATION FOR SUBSTANTIAL SHAREHOLDER - U.I.P. HOLDINGS LIMITEDSGX · 2026/9/14
-
公司公告
FLOWING CLOUD: REVISED EXPECTED TIMETABLE IN RELATION TO(I) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL;(II) PROPOSED CHANGE IN BOARD LOT SIZE;AND(III) PROPOSED RIGHTS ISSUE ON THE BASIS OFFOUR (4) RIGHTS SHARES FOR EVERY ONE (1) SHAREHELD ON THE RECORD DATE ON A NON-UHKEX · 2026/10/5
-
U.S. Stock Market Moves | Ferrovial rises 3.6% in pre-market trading after securing $9.2 billion public-private partnership for Tennessee I-24 Express LanesGelonghui Finance · 2026/8/20
-
U.S. Treasury Secretary Bessent: Trump and I have full confidence in Federal Reserve Chair WarshBreakings · 2026/9/21
-
U.S. stocks are clearly in a state of "euphoria"! Howard Marks: This is one of the most challenging situations I have encountered in my investment career, but uncertainty about the future is not a reason to refrain from investing...The Intelligent Investor · 2026/9/7
-
公司公告
ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF PHASE I STUDY IN U.S.FOR ORAL AMYLIN RECEPTOR PEPTIDE AGONIST ASC36 FOR THETREATMENT OF OBESITYHKEX · 2026/9/8
新闻标题为自动聚合内容,未经我们团队独立核实或编辑。
报价时间 2026-10-16 20:01:23 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
凯睿思生命科学 讨论区 0 条评论